Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

C003 - Avoiding and Managing Filler Complications

Friday, February 16; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Review types of complications that can be seen with the use of filler soft-tissue augmentation agents.
  • Discuss methods of treatment for each of these filler complications.


This session will review the spectrum of potential filler complications from superficial bumps and swelling, to nodules, to granulomas and to vascular compromise and necrosis. An emphasis will be placed on reviewing treatment algorithms for these types of issues. Regional anatomic considerations and pearls will be discussed. And new this year, data from the FDA will be presented as well.


  • Avram, Mathew M., MD, JD: Alastin Skincare, Inc – C(Fees); Allergan, Inc – C(Fees); Cytrellis Biosystems, Inc – C(ST); Invasix – C(Fees); Masters of Aesthetics, Inc. – F(Fees); Merz Aesthetics – C(Fees); Sciton Inc. – A(Fees); Sienna Biopharmaceuticals – A(Fees); Zalea, LLC – C(Fees); Zeltiq Aesthetics – C(Fees);
  • Braz, Andre, MD: Allergan, Inc – A(H), SP(H); Merz Pharmaceuticals, LLC – SP(Fees);
  • Chiu, Annie, MD: Aclaris Therapeutics Inc. – SP(H); Allergan, Inc. – A(H), C(Fees), I(Grants/Research Funding); Boots – SP(Fees); BTL Industries – SP(H); Burt's Bees – C(Fees); Cynosure – I(EQ); Evolus, Inc. – A(H); La Roche-Posay Laboratorie Pharmaceutique – C(Fees); Merz Aesthetics – A(Fees); Obagi Medical Products – C(H); Ortho Dermatologics – SP(H); Revance Therapeutics, Inc. – A(H); SkinCeuticals LLC – A(Fees); SkinMedica, Inc. – SP(H); Unilever – C(Fees);
  • Cohen, Joel Lee, MD: Allergan, Inc. – C(H); Brickell Biotech, Inc. – I(Grants/Research Funding); Ferndale Laboratories, Inc. – I(Grants/Research Funding); Galderma USA – C(H), I(Grants/Research Funding); Merz Aesthetics – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – C(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Sciton Inc. – C(H);
  • Downie, Jeanine B., MD: Aclaris Therapeutics Inc. – C(H); Allergan, Inc. – C(H), SP(H); Alphaeon – C(H); BTL Industries – C(H); Cutera, Inc. – C(H); Galderma Laboratories, L.P. – C(H), SP(H); Innocutis – C(H); Intendis, Inc. – C(H); Johnson & Johnson Consumer Products Company – C(H), I(H), SP(H); Kythera – I(H); LaViv – C(H); Lifes2Good – C(H); Medicis Pharmaceutical Corporation – C(H), SP(H); Medimetriks Pharmaceuticals, Inc. – C(H); Merz Pharmaceuticals, LLC – C(H), O(Grants/Research Funding); Neothetics – C(H); Novartis Pharmaceuticals Corp. – C(H); Nutrafol – C(H); Perigee Medical LLC – C(H); Pfizer Inc. – C(H); Procter & Gamble Company – C(H); Ranbaxy Laboratories Limited – C(H); Restorsea LLC – C(H); Revance Therapeutics, Inc. – C(H), I(H); Sente Labs – C(H); SkinMedica, Inc. – C(H), SP(H); Stratamed – C(H); Theraplex – C(H); ThermiRF/Almirall – C(H); Valeant Pharmaceuticals North America LLC – C(H);
  • Green, Jeremy, MD: Aclaris Therapeutics Inc. – A(H); Allergan, Inc – A(H), I(Grants/Research Funding), SP(H); Bonti – A(H); Brickell Biotech, Inc. – I(Grants/Research Funding); Candesant Biomedical, Inc. – I(Grants/Research Funding), SH(ST); Clarisonic – A(H); Cutera, Inc. – SP(H); Cynosure, Inc. – SP(EQ); Endo International plc – A(H); Evolus, Inc. – A(H); Galderma Laboratories, L.P. – I(Grants/Research Funding), SP(H); Galderma USA – A(H); Lutronic – I(Grants/Research Funding); Merz Aesthetics – A(H), I(Grants/Research Funding), SP(H); Pulse Biosciences – I(Grants/Research Funding); Revance Therapeutics, Inc. – A(H), I(Grants/Research Funding); Sienna Labs, Inc. – A(H), I(Grants/Research Funding);
  • Matarasso, Seth L., MD: no financial relationships exist with commercial interests.
  • Ortiz, Arisa, MD: Aerolase – A(H), O(EQ); Alastin Skincare, Inc – C(H); Allergan, Inc – A(H), SH(NC), SP(H); BTL Industries – O(EQ); Cutera, Inc. – C(H); Guthy-Renker – SP(S); InMode MD Ltd – A(H), SP(H); Merz Aesthetics – A(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Rodan and Fields – A(H); Sciton Inc. – A(H), SP(H); Sienna Biopharmaceuticals – I(Grants/Research Funding); Ulthera – Data Safety Monitoring Board(H);
  • Ozog, David M., MD: Biofrontera AG – I(Grants/Research Funding), SH(NC); Galderma USA – I(Grants/Research Funding); miRagen Therapeutics, Inc. – I(Grants/Research Funding);
Friday, February 16
9:00 AM
Dr. Avram / Legal Considerations of Filler Complications
9:20 AM
Dr. Ortiz / Managing Filler Complications with Lasers and Devices
9:30 AM
Dr. Braz / Anatomy with Focus on Upper Half of Face
9:55 AM
/ Questions
10:05 AM
Dr. Cohen / Vessels and Impending Necrosis
10:30 AM
Dr. Matarasso / Cases and Nodules
10:45 AM
Dr. Ozog / Dorsal Hand
11:00 AM
/ Questions
11:05 AM
Dr. Downie / Cases and Filler Considerations in Skin of Color
11:20 AM
Dr. Chiu / Forehead and Temples
11:35 AM
Dr. Green / Peri-Oral
11:50 AM
/ Questions
Event Details
  • Date
    Friday, February 16
  • Time
    9:00 AM - 12:00 PM
  • Location
    Room 7B
  • CME Credits
  • Type
  • Andre Braz, MD
  • Annie Chiu, MD, FAAD
  • Arisa Ortiz, MD, FAAD - Handout
  • David M. Ozog, MD, FAAD
  • Jeanine B. Downie, MD, FAAD
  • Jeremy Green, MD, FAAD
  • Mathew M. Avram, MD, JD, FAAD
  • Seth L. Matarasso, MD, FAAD